Abiomed (ABMD) Holder Dorsey Wright & Associates Has Trimmed Stake as Stock Declined; Caprock Group Increased Its Citigroup (C) Holding by $319,074

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Dorsey Wright & Associates decreased its stake in Abiomed Inc (ABMD) by 5.69% based on its latest 2018Q3 regulatory filing with the SEC. Dorsey Wright & Associates sold 1,518 shares as the company’s stock declined 16.71% with the market. The institutional investor held 25,151 shares of the health care company at the end of 2018Q3, valued at $11.31M, down from 26,669 at the end of the previous reported quarter. Dorsey Wright & Associates who had been investing in Abiomed Inc for a number of months, seems to be less bullish one the $16.07B market cap company. The stock decreased 0.44% or $1.58 during the last trading session, reaching $356.5. About 94,978 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 72.24% since February 13, 2018 and is uptrending. It has outperformed by 72.24% the S&P500. Some Historical ABMD News: 04/04/2018 – Abiomed Announces European Approval (CE Marking) for lmpella 5.5™ and First Patient Treated at University Heart Center Hamburg; 04/04/2018 – ABIOMED INC – OVER NEXT FISCAL YR, PLANS TO LAUNCH IMPELLA 5.5 HEART PUMP THROUGH A CONTROLLED ROLL-OUT AT GERMAN HOSPITALS; 03/05/2018 – Abiomed 4Q Rev $174.4M; 08/03/2018 DOJ Contends Abiomed Sought to Induce Physicians to Use Pumps; 23/04/2018 – DJ ABIOMED Inc, Inst Holders, 1Q 2018 (ABMD); 02/04/2018 – ABIOMED GETS FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ & O; 03/05/2018 – ABIOMED 4Q EPS 80C, EST. 64C; 03/05/2018 – Abiomed 4Q Net $36.8M; 02/04/2018 – Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor; 05/04/2018 – Abiomed Announces European Approval (CE Marking) for lmpella 5.5(TM) and First Patient Treated at University Heart Center Hamburg

Caprock Group Inc increased its stake in Citigroup Inc (C) by 23.33% based on its latest 2018Q3 regulatory filing with the SEC. Caprock Group Inc bought 4,494 shares as the company’s stock declined 18.04% with the market. The institutional investor held 23,758 shares of the major banks company at the end of 2018Q3, valued at $1.70 million, up from 19,264 at the end of the previous reported quarter. Caprock Group Inc who had been investing in Citigroup Inc for a number of months, seems to be bullish on the $150.09 billion market cap company. The stock increased 1.12% or $0.7 during the last trading session, reaching $63.37. About 4.20 million shares traded. Citigroup Inc. (NYSE:C) has declined 23.89% since February 13, 2018 and is downtrending. It has underperformed by 23.89% the S&P500. Some Historical C News: 31/03/2018 – Corporate Life: Morgan Stanley, Citi plan Brexit job moves – sources| Reuters; 28/03/2018 – Citigroup Announces Redemption of Series E Preferred Stk; 13/04/2018 – Citigroup, Wells Fargo and J.P. Morgan Chase all reported quarterly earnings and revenue that surpassed analyst expectations; 27/04/2018 – CITIGROUP FILES $100M MIXED SECURITIES SHELF; 04/04/2018 – Citigroup at Capital Link Singapore Maritime Forum Apr 24; 28/03/2018 – Citigroup: Tier 1 Capital Ratio to Decrease by 1 Basis Point; 06/04/2018 – Citi Research says Trump’s tariff announcements aren’t as hostile as they appear; 07/05/2018 – Citi Private Bank Hails Fernando Alonso’s Superb World Endurance Championship Debut Race Win; 19/04/2018 – Citigroup at Capital Link International Shipping Forum Tomorrow; 10/04/2018 – TEXTRON INC TXT.N : CITIGROUP RAISES TARGET PRICE TO $67 FROM $61

Dorsey Wright & Associates, which manages about $743.59M and $548.86 million US Long portfolio, upped its stake in Align Technology Inc (NASDAQ:ALGN) by 8,157 shares to 20,980 shares, valued at $8.21 million in 2018Q3, according to the filing. It also increased its holding in Bio Rad Labs Inc Cl A (NYSE:BIO) by 15,059 shares in the quarter, for a total of 23,492 shares, and has risen its stake in Pbf Energy Inc Cl A (NYSE:PBF).

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Seekingalpha.com which released: “Abiomed’s Impella Connect CE Mark’d – Seeking Alpha” on January 31, 2019, also Nasdaq.com with their article: “Abiomed (ABMD) Gains But Lags Market: What You Should Know – Nasdaq” published on January 25, 2019, Nasdaq.com published: “ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum – Nasdaq” on February 01, 2019. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Nasdaq.com and their article: “Top Ranked Momentum Stocks to Buy for February 11th – Nasdaq” published on February 11, 2019 as well as 247Wallst.com‘s news article titled: “5 Stocks That Struggled in 2018 Could Be Big 2019 Winners – 24/7 Wall St.” with publication date: January 28, 2019.

Among 15 analysts covering Abiomed (NASDAQ:ABMD), 14 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Abiomed had 40 analyst reports since August 4, 2015 according to SRatingsIntel. Morgan Stanley maintained ABIOMED, Inc. (NASDAQ:ABMD) on Friday, February 2 with “Equal-Weight” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, November 2 by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, September 21 by Jefferies. On Friday, February 2 the stock rating was maintained by Stephens with “Buy”. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, August 5. The firm earned “Neutral” rating on Monday, October 16 by BTIG Research. As per Thursday, January 4, the company rating was maintained by Piper Jaffray. Morgan Stanley upgraded the stock to “Overweight” rating in Wednesday, November 7 report. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Leerink Swann on Thursday, October 12. Jefferies maintained the stock with “Buy” rating in Thursday, February 1 report.

Since August 29, 2018, it had 0 insider buys, and 5 insider sales for $27.12 million activity. Greenfield Andrew J sold $1.75 million worth of stock. $4.33 million worth of stock was sold by Howley Michael G on Tuesday, September 25. $8.44M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by Weber David M.

Investors sentiment decreased to 1.21 in 2018 Q3. Its down 0.40, from 1.61 in 2018Q2. It fall, as 35 investors sold ABMD shares while 144 reduced holdings. 77 funds opened positions while 139 raised stakes. 35.84 million shares or 0.84% less from 36.14 million shares in 2018Q2 were reported. Moreover, Axiom Int Invsts Ltd Limited Liability Company De has 0.44% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 34,404 shares. Utd Fincl Advisers Ltd Liability Company reported 683 shares stake. 17 were accumulated by Fifth Third Comml Bank. Wilbanks Smith And Thomas Asset Ltd Company, a Virginia-based fund reported 2,076 shares. Rmb Cap Mgmt Limited Company reported 12,858 shares stake. Chevy Chase Trust Inc stated it has 36,868 shares. Bnp Paribas Asset Mngmt Sa reported 15,624 shares. British Columbia Inv Management, a British Columbia – Canada-based fund reported 25,742 shares. Signaturefd Ltd Liability Corporation holds 0.11% or 2,423 shares. Mutual Of America Capital Mngmt Limited Liability reported 6,195 shares. Envestnet Asset has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). Wells Fargo And Communication Mn, California-based fund reported 142,616 shares. Advisory Research holds 0.01% or 1,234 shares in its portfolio. 1832 Asset Management Lp has 0.27% invested in ABIOMED, Inc. (NASDAQ:ABMD). Cleararc Incorporated stated it has 0.07% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD).

Among 40 analysts covering Citigroup Inc. (NYSE:C), 25 have Buy rating, 2 Sell and 13 Hold. Therefore 63% are positive. Citigroup Inc. had 136 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Wednesday, January 17 by Wood. The stock of Citigroup Inc. (NYSE:C) has “Outperform” rating given on Friday, November 10 by Macquarie Research. Goldman Sachs downgraded Citigroup Inc. (NYSE:C) on Friday, September 16 to “Neutral” rating. The firm earned “Market Perform” rating on Friday, October 13 by BMO Capital Markets. The firm earned “Buy” rating on Friday, October 13 by Buckingham Research. Societe Generale downgraded Citigroup Inc. (NYSE:C) on Tuesday, September 13 to “Sell” rating. Deutsche Bank maintained the shares of C in report on Thursday, September 27 with “Buy” rating. As per Tuesday, January 5, the company rating was downgraded by KeyBanc Capital Markets. The stock of Citigroup Inc. (NYSE:C) earned “Hold” rating by BMO Capital Markets on Friday, April 13. The company was maintained on Tuesday, January 8 by Morgan Stanley.

Investors sentiment is 1.02 in Q3 2018. Its the same as in 2018Q2. It is flat, as 52 investors sold C shares while 470 reduced holdings. only 122 funds opened positions while 410 raised stakes. 1.80 billion shares or 3.35% less from 1.86 billion shares in 2018Q2 were reported. Vantage Invest Limited Liability stated it has 0.01% of its portfolio in Citigroup Inc. (NYSE:C). M stated it has 25,742 shares or 0.48% of all its holdings. Clinton Group Inc reported 25,000 shares. Stephens Ar reported 0.14% in Citigroup Inc. (NYSE:C). Moreover, Fjarde Ap has 0.72% invested in Citigroup Inc. (NYSE:C). Dupont Management Corp has invested 0.65% in Citigroup Inc. (NYSE:C). Uss Investment stated it has 1.15% of its portfolio in Citigroup Inc. (NYSE:C). Mitchell Mcleod Pugh And Williams accumulated 8,465 shares. Cambridge Tru reported 3,719 shares. Oldfield Prtnrs Llp, United Kingdom-based fund reported 1.09M shares. Nomura Asset Mngmt Co Limited invested in 803,611 shares or 0.56% of the stock. Balasa Dinverno And Foltz Ltd Limited Liability Company holds 15,776 shares or 0.13% of its portfolio. Macquarie Gp stated it has 0.04% in Citigroup Inc. (NYSE:C). Illinois-based Harris Associate Limited Partnership has invested 4.41% in Citigroup Inc. (NYSE:C). Norinchukin Bancorporation The stated it has 0.17% in Citigroup Inc. (NYSE:C).

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart